Search Orphan Drug Designations and Approvals
-
| Generic Name: | riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Photrexa Viscous | ||||||||||||||||
| Date Designated: | 12/02/2011 | ||||||||||||||||
| Orphan Designation: | Treatment of corneal ectasia following refractive surgery | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Glaukos Corporation One Glaukos Way Aliso Viejo, California 92656 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation |
|---|---|---|
| Trade Name: | Photrexa Viscous | |
| Marketing Approval Date: | 07/15/2016 | |
| Approved Labeled Indication: | Treatment of corneal ectasia following refractive surgery | |
| Exclusivity End Date: | 07/15/2023 | |
| Exclusivity Protected Indication* : | Treatment of corneal ectasia following refractive surgery | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







